[PDF] Top 20 The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia

... whether the sequencing of cyclophosphamide (Cy) and total body irradiation (TBI) changes ...evaluated the sequence in 1769 (CyTBI, n ¼ 948; TBICy, n ¼ ... Voir le document complet

... Patients and methods Study design and data collection This was a retrospective, multicenter analysis using the dataset of the ALWP of the ...EBMT. The EBMT ... Voir le document complet

... Allogenic hematopoietic stem cell transplantation (allo-SCT) is the most effective post-remission treatment for adults with high-risk acute lymphoblastic leukemia ... Voir le document complet

... pre- and post-transplant disease response, OS, PFS, transplant-related mortality (TRM), dis- ease progression, and cumulative incidences of acute and chronic graft-versus-host disease ... Voir le document complet

... 2 total dose) plus amsacrine (400 mg/m 2 total dose)) or an association of clofarabine (150 mg/m 2 total dose) and cytarabine (5 g/m 2 total dose) followed by a RIC (4 Gy TBI, or ... Voir le document complet

... woman with biphenotypic Ph-chromosome- positive acute leukemia in first relapse underwent an allogene- ic CD34-selected ...stem cell transplant from an unrelated male donor after a ... Voir le document complet

... Group for Blood and Marrow Transplantation (EBMT). The EBMT registry is a voluntary working group of more than 500 transplant centers; its participants are required once a year to ... Voir le document complet

... number of other factors may contribute to these ...low for the degree of anemia are observed after amphotericin B administration (Lin et ...finding in HSCT recipients (Schapira et al. ... Voir le document complet

... n×n with nonnegative off-diagonal terms is called Metzler matrix, the matrix A is called nonnegative if all its entries are ...Stability of the model of cell dynamics in ... Voir le document complet

... regions with low buildup (i.e., low-density regions and the first few millimeters under the skin), optimization algorithms increase the photon ...fluence. For very low densities, ... Voir le document complet

... criteria for this analysis included adult patients (ages > 18 years) with a diagnosis of ...sAML. Patients with sAML were defined as patients di- agnosed with AML ... Voir le document complet

... endpoints of the study were incidences and se- verity of acute and chronic GVHD, NRM, and disease relapse incidence ...OS, and LFS. Start time was the date ... Voir le document complet

... Besides the classical risk factors, i.e., cytogenetics and age, as well as donor type, our data identify sAML as an independent intrinsic factor for inferior outcome after alloSCT in ... Voir le document complet

... Discussion The COVID-19 pandemic has resulted in previously unprecedented challenges to transplant programs and phy- sicians performing stem cell ...WHO and other international ... Voir le document complet

... Open in new tab | Download powerpoint performance status, conditioning regimen (myeloablative or reduced- intensity conditioning), graft type (peripheral blood, bone marrow or cord blood), donor and ... Voir le document complet

... Discussion In the last WHO classi fication of myeloid malignancies, a provisional entity of AML with mutated RUNX1 was added for patients diagnosed with de novo AML ... Voir le document complet

... of induction failure or relapse and a poor outcome ...role in signaling pathways downstream to cytokine receptors that are important in T-ALL and central to ETP ALL oncogenesis ... Voir le document complet

... effects of chronic GVHD? Previous studies in the bone marrow or peripheral blood setting have demonstrated a strong link between chronic GVHD occurrence and a lower risk of relapse ... Voir le document complet

... mainly in Europe. The EBMT promotes all activity aiming to improve stem cell transplantation or cellular therapy, which includes regis- tering all the activity relating to stem ... Voir le document complet

... factors for treatment outcome, such as tumor mass (WBC more than 30 × 10 9 /L) and the patient’s age (> 35 years of age), had no impact on the difference in outcome according ... Voir le document complet